DAX24.292 +1,4%Est505.882 ±0,0%MSCI World4.343 -0,1%Top 10 Crypto10,07 +2,7%Nas25.114 +0,9%Bitcoin68.111 +1,7%Euro1,1733 -0,1%Öl107,4 -1,7%Gold4.613 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 SAP 716460 Infineon 623100 Amazon 906866 Lufthansa 823212 Microsoft 870747 Siemens Energy ENER6Y Volkswagen (VW) vz. 766403 Allianz 840400 NEL ASA A0B733 Alphabet A (ex Google) A14Y6F BASF BASF11 Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fester erwartet -- Asiens Börsen in Grün -- Autozölle dürften VW & Co. belasten - Berkshire Hathaway setzt mehr um -- GameStop will wohl eBay übernehmen -- E.ON, UBS, Deutsche Bank, Merck im Fokus
Top News
Walmart, Coca-Cola & Co.: Die Top-Dividendenaktien der Wall Street-Analysten für 2026 Walmart, Coca-Cola & Co.: Die Top-Dividendenaktien der Wall Street-Analysten für 2026
Ausblick: Lucid Group legt Zahlen zum jüngsten Quartal vor Ausblick: Lucid Group legt Zahlen zum jüngsten Quartal vor
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Xencor Aktie

Kaufen
Verkaufen
Xencor Aktien-Sparplan
10,60 EUR +0,50 EUR +4,95 %
STU
12,69 USD +0,76 USD +6,37 %
BTT
finanzen.net zero
Xencor jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.793,48 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W96L

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS98401F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolXNCR

Xencor Aktien News

DatumMeistgelesen
BenzingaRoyalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
ZacksXencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
BenzingaXencor Faces Structural Headwinds As Long-Term Momentum Fades
Wer­bungXencor-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
ZacksXencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates
ZacksStrength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
BenzingaBeyond The Numbers: 4 Analysts Discuss Xencor Stock
ZacksXencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
MotleyFoolXencor (XNCR) Q2 Revenue Jumps 82%
ZacksXencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
BusinesswireXencor to Participate at Upcoming Investor Conferences
BusinesswireXencor Reports Third Quarter 2024 Financial Results
BusinesswireXencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
BusinesswireXencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
BusinesswireXencor Announces Upcoming Change to Board of Directors
BusinesswireXencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BusinesswireXencor Announces Pricing of $175 Million Public Offering of Common Stock
BusinesswireXencor Announces Proposed Public Offering of Common Stock
BusinesswireXencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
BusinesswireXencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
BusinesswireXencor Reports Second Quarter 2024 Financial Results
BusinesswireXencor Regains CD20 x CD3 Bispecific T-Cell Engager
BusinesswireXencor Reports First Quarter 2024 Financial Results
BusinesswireXencor Appoints Bart Cornelissen as Chief Financial Officer
BusinesswireXencor to Present at Upcoming Investor Conferences
BusinesswireXencor Reports Fourth Quarter and Full Year 2023 Financial Results
BusinesswireXencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
BusinesswireXencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BusinesswireDane Leone Joins Xencor as Senior Vice President, Corporate Strategy
BusinesswireXencor to Present at the Piper Sandler 35th Annual Healthcare Conference
BusinesswireXencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
BusinesswireXencor Reports Third Quarter 2023 Financial Results
BusinesswireXencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
BusinesswireXencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
BusinesswireXencor Announces Planned Retirement of Chief Financial Officer John Kuch
BusinesswireXencor to Present Multiple Posters at the SITC Annual Meeting
BusinesswireXencor Appoints Barbara J. Klencke, M.D., to Board of Directors
BusinesswireXencor Reports Second Quarter 2023 Financial Results
BusinesswireXencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
BusinesswireXencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
BusinesswireXencor Reports First Quarter 2023 Financial Results

Xencor News

Xencor News: auf dieser Seite finden Sie alle Xencor News und Nachrichten zur Xencor Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Xencor News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Xencor News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.